Sign In

Press release centre

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

Past Press Releases - Life Sciences Partners (LSP)

January 20, 2016
LSP Leads Financing Round in Insulin Pump Company ViCentra
LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series B Round of ViCentra B.V., a private Dutch company commercializing the Kaleido insulin pump system for diabetes patients. More

November 12, 2015
LSP’s portfolio company Curetis raises EUR 40 million in successful Euronext IPO.
Our portfolio company Curetis N.V., a developer of advanced molecular diagnostic assays for severe infectious diseases in hospitalized patients, raised € 40 million in an initial public offering (IPO) through a listing in Euronext Amsterdam and Euronext Brussels. More

August 18, 2015
Kuros Announces the Successful Closing of a CHF 15m Financing Round
Kuros Biosurgery AG, a biotechnology company developing novel biomaterials and bioactive-biomaterial combination products and focused in therapeutic areas covering sealants and orthobiologics, announced today that it has closed a financing round of CHF15M. More

May 11, 2015
PMV and LSP enter into strategic partnership in life sciences
ParticipatieMaatschappij Vlaanderen (PMV) and Life Sciences Partners (LSP) today announce entering into a strategic partnership to further build and strengthen Flanders’ life sciences industry, benefitting from each other’s complementary networks, skills and expertise. More

September 30, 2014
LSP raises EUR 80 mln to invest in medical innovations
LSP (Life Sciences Partners) today announced that it has raised EUR 80 mln (USD 100 mln) for its new fund LSP 5. More

September 15, 2014
It is with great pleasure that today, LSP – the specialist European healthcare investment firm – announces that its portfolio company Affimed was successfully listed on the NASDAQ stock exchange. More

July 10, 2014
LSP’s portfolio company arGEN-X raises targeted EUR 40 million in successful IPO on Euronext
It is with great pleasure that today, LSP – the specialist European healthcare investment firm – announces that its portfolio company arGEN-X was successfully listed on the Euronext Brussels stock exchange on Thursday July 10 under the ticker “ARGX” at a market capitalization of EUR 132 mln. More

February 10, 2012
Achmea and LSP launch the LSP-Health Economics Fund for innovation in health care
Dutch health care insurer Achmea and investment company Life Sciences Partners (LSP) have set up an investment fund for innovation in health care, the LSP-Health Economics Fund (LSP-HEF). More

January 12, 2011
LSP's portfolio company EyeSense attracts QIAGEN as strategic investor
Strategic partnership to develop and commercialize a novel ophthalmic self-diagnostic system for blood glucose monitoring by diabetes patients. More

May 27, 2010
LSP announces acquisition of portfolio company FlowCardia, Inc.
LSP is pleased to announce that its portfolio company, FlowCardia, Inc., has been acquired by C.R. Bard, Inc. Bard is a worldwide leader in products that focus on disease state management in three key areas: vascular, urology and oncology. More

September 10, 2009
LSP co-leads EUR 9.5 million Series A financing of arGEN-X
LSP (Life Sciences Partners) announced today the closure of the Series A financing round of arGEN-X, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody platform. More

December 17, 2008
LSP's portfolio company Prosensa raises EUR 18 million Series B financing
LSP's portfolio company Prosensa Holding B.V., a Netherlands based biotechnology company focused on RNA interference therapeutics using exon skipping technology, today announced that it has closed an EUR 18 million series B round. More

November 6, 2008
LSP raises € 75 mln for new life sciences venture fund
GSK and Pfizer among the investor group. More

May 21, 2008
LSP announces acquisition of portfolio company U3 Pharma AG
LSP announced today that it has entered into an agreement with Daiichi Sankyo Co. Ltd. for Daiichi Sankyo to acquire LSP portfolio company, U3 Pharma AG. More

April 28, 2008
APG and LSP announce strategic investment relationship
The LSP (Life Sciences Partners) Group, the European life sciences investment group, today announces the establishment of a strategic investment relationship with APG Investments. More

January 15, 2008
LSP co-leads CHF 17.0 million Series A financing of Vivendy Therapeutics AG
LSP today announced the closing of a CHF 17.0 million Series A round of Vivendy Therapeutics Ltd., a bio-pharmaceutical company located in Basel, Switzerland. More

December 19, 2007
BMEYE announces FDA 510(K) clearance for Nexfin
LSP’s portfolio company BMEYE announced that it has received 510(K) clearance from the U.S. Food and Drug Administration (FDA) to market Nexfin, their newly developed line of safe, precise and easy to use hemodynamic monitors. More

October 5, 2007
LSP co-leads Series A financing round of Skyline Diagnostics
LSP (Life Sciences Partners) announced today the closure of the Series A financing round of Skyline Diagnostics B.V. More

September 10, 2007
LSP's portfolio company IDEA AG agrees on $ 202 million licensing deal with Alpharma
LSP announces today that the German drug delivery company IDEA AG has agreed with an affiliate of Alpharma Inc., Bridgewater/NJ to license the exclusive United States rights to Diractin (ketoprofen in Transfersome, formerly known as IDEA-033) as a prescription topical NSAID (non-steroidal anti-inflammatory drug) in the US. More

August 8, 2007
LSP BioVentures leads $10 million Series C investment in BioProcessors
LSP BioVentues announces today that it has lead the closing of a $10 million Series C equity investment round in BioProcessors Corporation, the leading provider of micro-engineered solutions for biopharmaceutical process development applications for the biotechnology and pharmaceutical industries. More


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Feb 14€19.0MBiopharmaceuticals
Feb 14N/AInternet services
Feb 14€4.6MBusiness applications
Feb 13€13.0MBiopharmaceuticals
Feb 13€25.0MMedical devices
Feb 13€15.0MBusiness applications

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.